Form 4: Lexaria Bioscience Corp. Director Acquires Additional Stock Options

Sentiment:

SEC Form 4 Filing


William McKechnie, a director of Lexaria Bioscience Corp., reports the acquisition of 11,000 stock options.

Summary

  • On May 15, 2025, William McKechnie, a director of Lexaria Bioscience Corp., acquired 11,000 stock options.
  • These options are exercisable at a price of $1.04 and expire on May 15, 2030.
  • The acquisition increases McKechnie's total holdings to 63,000 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option acquisition by a director, which doesn't inherently indicate positive or negative sentiment.

Positives

  • Director McKechnie's acquisition of additional stock options may signal confidence in the company's future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders.

Stakeholder Impact

  • The acquisition of stock options by a director could be viewed positively by shareholders, as it may align the director's interests with those of the shareholders.

Key Dates

DateDescription
04/26/2021Date of exercisable stock options with expiration date 04/26/2026.
06/08/2021Date of exercisable stock options with expiration date 06/08/2026.
09/01/2021Date of exercisable stock options with expiration date 09/01/2026.
03/08/2022Date of exercisable stock options with expiration date 03/08/2027.
10/12/2022Date of exercisable stock options with expiration date 10/12/2027.
07/25/2023Date of exercisable stock options with expiration date 07/25/2028.
04/26/2024Date of exercisable stock options with expiration date 04/26/2029.
07/26/2024Date of exercisable stock options with expiration date 07/26/2029.
05/15/2025Date of transaction: Director William McKechnie acquired 11,000 stock options exercisable on 05/15/2025 and expiring on 05/15/2030.
05/16/2025Date of signature.
05/15/2030Expiration date of stock options acquired on 05/15/2025.

Keywords

stock options, director, Form 4, Lexaria Bioscience Corp., LEXX, beneficial ownership, McKechnie

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.